Developer of therapeutic drugs for sexually transmitted diseases. It offfer therapeutics that improve health outcomes for patients suffering from diseases caused by HPV and other viruses. Its lead drug program is aimed at intervening before lesions in the cervix and anus become cancerous. The lead molecule ABI-1968 is a topical therapeutic for the treatment of oncogenic HPV infection and pre-cancerous moderate to high-grade cervical intraepithelial neoplasias.
← All startups
Antiva Biosciences
Series EDeveloper of therapeutic drugs for sexually transmitted diseases. It offfer therapeutics that improve health outcomes for patients suffering from diseases caused by HPV and other viruses. Its lead drug program is aimed at intervening before lesions in the cervix and anus become cancerous. The lead molecule ABI-1968 is a topical therapeutic for the treatment of oncogenic HPV infection and pre-cancerous moderate to…
About
Institutional investors
Brace Pharma CapitalSofinnova InvestmentsCanaanTimefolio CapitalOsage University PartnersAlexandriaHillhouseSirona CapitalLumira VenturesAdjuvant CapitalGoogle VenturesAvestria Ventures
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.